Stephen J. Farr, Ph.D.
Stephen J. Farr, Ph.D. is one of our co-founders, a member of our board of directors and has served as our Chief Executive Officer since April 2015, leading our strategy on developing drugs in rare orphan neurological disorders. In his original role as President and Chief Operating Officer since the founding of Zogenix in 2006, Dr. Farr led the development and FDA approval of the Company’s first two drug products. Prior to starting Zogenix, Dr. Farr held positions of increasing responsibility at Aradigm Corporation from 1995 to 2006. His last position was Aradigm’s Sr. Vice President and Chief Scientific Officer, with responsibility for research and development as well as business development. From 1986 to 1994, Dr. Farr was a tenured professor at the Welsh School of Pharmacy, Cardiff University, United Kingdom, concentrating in the areas of biopharmaceutics. While there, he built an internationally recognized research group working in drug delivery science with a focus on pulmonary drug delivery.
Dr. Farr is a member of the board of directors of SteadyMed (NASDAQ: STDY) and two private companies, Oscillari, LLC and Flow Pharma, Inc. He is author/co-author of over 180 scientific publications and patents and retains his academic interests as adjunct Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, USA. Dr. Farr received a BSc (Hons) Pharmacy degree from De Montfort University, UK and holds his Ph.D. degree in Pharmaceutics from the University of Wales.